A Double-Blind, Placebo-Controlled Randomized Phase IIa Study: Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Solid Cancer Patients
- PMID: 35901339
- PMCID: PMC9727370
- DOI: 10.31557/APJCP.2022.23.7.2333
A Double-Blind, Placebo-Controlled Randomized Phase IIa Study: Evaluating the Effect of Curcumin for Treatment of Cancer Anorexia-Cachexia Syndrome in Solid Cancer Patients
Abstract
Objective: We aim to investigate the effect of curcumin on preventing cancer anorexia-cachexia syndrome (CACS) via through mechanism of inhibition on NF-kB signal pathway. Outcome measurement for primary end point was improvement of body tissue composition, and the secondary end points were body weight and body mass index, hand grip muscle strengthening, and safety.
Methods: This is randomized, double-blind, placebo-controlled phase ll a study, 33 patients with CACS in solid malignancy were enrolled and randomized in 1:1 to receive oral curcumin (at a dose of 800 mg twice daily) or placebo for 8 weeks.
Results: All parameters of body compositions were not statistically significant different between two groups, which were consist body fat mass [-1.25(SEM 0.87) vs. +0.63(SEM 0.55); p=0.119], skeletal muscle mass [-0.35(SEM 0.60) vs.+0.33(SEM 0.42); p=0.408] and percent body fat [-0.47(SEM 0.95) vs. -0.29(SEM 0.82); p=0.893] including with basal metabolic rate [-13.47(SEM 21.94) vs. +15.30(13.76); p=0.336]. The average of weight loss was also not statistically significant different between two groups. [-1.4 kg(SEM 0.89) in curcumin vs-1.12 kg(SEM 0.73), p=0.810]. Notably, patient with curcumin had less reduction of hand-grip muscle strength on both hands [Rt. handed: -2.47 in curcumin vs. -5.36 in placebo; p=0.318] [Lt. handed: -1.98 vs. -5.43; p=0.317], and basal metabolic rate than placebo group. Most adverse events were grade 1 on both groups similarly.
Conclusion: Curcumin was not shown to be superior to placebo with regard to increasing the body composition in cancer patients with CACS. However, curcumin might show some clinical benefits, including slow progression of hand-grip muscle strength loss, and basal metabolic rate. Further investigations should be explored.
Keywords: Cancer anorexic cachexia; cancer cachexia; curcumin.
Conflict of interest statement
The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangement), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
Similar articles
-
Efficacy of Curcumin on Treating Cancer Anorexia-Cachexia Syndrome in Locally or Advanced Head and Neck Cancer: A Double-Blind, Placebo-Controlled Randomised Phase IIa Trial (CurChexia).J Nutr Metab. 2022 Jun 2;2022:5425619. doi: 10.1155/2022/5425619. eCollection 2022. J Nutr Metab. 2022. PMID: 35694030 Free PMC article.
-
Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.J Pain Symptom Manage. 2021 Dec;62(6):1207-1215. doi: 10.1016/j.jpainsymman.2021.05.017. Epub 2021 May 26. J Pain Symptom Manage. 2021. PMID: 34051293 Clinical Trial.
-
The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study.J Palliat Med. 2012 Oct;15(10):1059-64. doi: 10.1089/jpm.2012.0146. Epub 2012 Aug 10. J Palliat Med. 2012. PMID: 22880820 Free PMC article. Clinical Trial.
-
The efficacy and safety of anamorelin for patients with cancer-related anorexia/cachexia syndrome: a systematic review and meta-analysis.Sci Rep. 2023 Sep 14;13(1):15257. doi: 10.1038/s41598-023-42446-x. Sci Rep. 2023. PMID: 37709824 Free PMC article.
-
Anamorelin for the Treatment of Cancer Anorexia-Cachexia Syndrome.Curr Oncol Rep. 2024 Jul;26(7):762-772. doi: 10.1007/s11912-024-01549-y. Epub 2024 May 21. Curr Oncol Rep. 2024. PMID: 38771469 Review.
Cited by
-
SARCOPENIA AND GASTROINTESTINAL CANCER: NUTRITIONAL APPROACH FOCUSING ON CURCUMIN SUPPLEMENTATION.Arq Gastroenterol. 2025 Apr 4;62:e24068. doi: 10.1590/S0004-2803.24612024-068. eCollection 2025. Arq Gastroenterol. 2025. PMID: 40197883 Free PMC article. Review.
-
Curcumin as a complementary treatment in oncological therapy: a systematic review.Eur J Clin Pharmacol. 2025 Jan;81(1):1-33. doi: 10.1007/s00228-024-03764-9. Epub 2024 Oct 19. Eur J Clin Pharmacol. 2025. PMID: 39425780 Free PMC article.
-
Treatment of Cachexia in Gastric Cancer: Exploring the Use of Anti-Inflammatory Natural Products and Their Derivatives.Nutrients. 2024 Apr 22;16(8):1246. doi: 10.3390/nu16081246. Nutrients. 2024. PMID: 38674936 Free PMC article. Review.
-
Phytochemicals as Chemo-Preventive and Therapeutic Agents Against Bladder Cancer: A Comprehensive Review.Diseases. 2025 Mar 30;13(4):103. doi: 10.3390/diseases13040103. Diseases. 2025. PMID: 40277814 Free PMC article. Review.
-
Natural Health Products for Anti-Cancer Treatment: Evidence and Controversy.J Pers Med. 2024 Jun 26;14(7):685. doi: 10.3390/jpm14070685. J Pers Med. 2024. PMID: 39063939 Free PMC article. Review.
References
-
- Aggarwal S, Ichikawa H, Takada Y, et al. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and metastatic gene products through suppression of InBa kinase and Akt activation. Mol Pharmacol. 2006;69:195–206. - PubMed
-
- Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21:2895–900. - PubMed
-
- Deodhar SD, Sethi R, Srimal RC. Preliminary study on antirheumatic activity of curcumin (diferuloyl methane) Indian J Med Res. 1980;71:632–4. - PubMed
-
- Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491–9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical